AnaptysBio, Inc. (ANAB)
| Market Cap | 768.82M |
| Revenue (ttm) | 101.27M |
| Net Income (ttm) | -8.71M |
| Shares Out | 27.39M |
| EPS (ttm) | -0.32 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 94,819 |
| Open | 28.41 |
| Previous Close | 28.53 |
| Day's Range | 27.71 - 28.65 |
| 52-Week Range | 17.72 - 35.85 |
| Beta | 0.05 |
| Analysts | Buy |
| Price Target | 35.33 (+23.7%) |
| Est. Earnings Date | Nov 4, 2021 |
About ANAB
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Imsidolimab, an IL-36R antibody that inhibits the interleukin-36 receptor for the treatment of various dermatological inflammatory diseases; ANB030, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through ANB030 treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable t...
Financial Performance
In 2020, AnaptysBio's revenue was $75.00 million, an increase of 837.50% compared to the previous year's $8.00 million. Losses were -$19.93 million, -79.52% less than in 2019.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for AnaptysBio stock is "Buy." The 12-month stock price forecast is 35.33, which is an increase of 23.75% from the latest price.
News
AnaptysBio Reveals Updated Imsidolimab Data In Severe Form Of Psoriasis
AnaptysBio Inc (NASDAQ: ANAB) has announced updated data from the GALLOP Phase 2 trial of imsidolimab in generalized pustular psoriasis (GPP). GPP is a rare and extreme form of psoriasis characterized b...
AnaptysBio Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized Pustular Psoriasis
SAN DIEGO, Oct. 02, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune cont...
AnaptysBio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune con...
AnaptysBio-Generated Antibody Scores Second FDA Approval For Solid Tumor Indication
The FDA has approved a second indication for GlaxoSmithKline plc's (NYSE: GSK) Jemperli (dostarlimab-gxly). The approval comes for adult patients with mismatch repair deficient (dMMR) recurrent or advan...
FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors
SAN DIEGO, Aug. 17, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune cont...
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of 86.67% and 8.87%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
AnaptysBio Announces Second Quarter 2021 Financial Results and Provides Pipeline Updates
SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune cont...
AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference
SAN DIEGO, May 27, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune contr...
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Misses Revenue Estimates
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of 7.04% and -1.45%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
AnaptysBio Announces First Quarter 2021 Financial Results and Provides Pipeline Updates
SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune contr...
Earnings Preview: AnaptysBio, Inc. (ANAB) Q1 Earnings Expected to Decline
AnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
European Commission Approves JEMPERLI (dostarlimab), the First Anti-PD-1 Therapy Approved for Recurrent or Advanced d...
SAN DIEGO, April 23, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune con...
FDA Approves JEMPERLI (dostarlimab-gxly) for dMMR Endometrial Cancer
SAN DIEGO, April 22, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune con...
AnaptysBio Announces Appointment of Oleg Nodelman to Board of Directors
SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune con...
Why AnaptysBio Stock Is Attractive After 30% Selloff
AnaptysBio Inc's (NASDAQ: ANAB) stock seems attractive after the POPLAR data and the 30% selloff, while there are several catalysts over the next 12-18 months, according to Truist Securities. AnaptysBio...
Why AnaptysBio Stock Is Popping Today
This analyst is excited about the company's prospects.
Why AnaptysBio Shares Rose Nearly 14% on Thursday
A phoenix may well rise from the ashes of a disappointing clinical trial.
AnaptysBio (ANAB) Plunges on Lead Candidate Study Failure
AnaptysBio's (ANAB) lead pipeline candidate, imsidolimab, fails to meet primary endpoint of a mid-stage study evaluating it in patients with auto-inflammatory disease, palmoplantar pustulosis.
Why AnaptysBio Plummeted Today
The company's leading drug candidate failed to meet its primary endpoint in a phase 2 clinical trial.
AnaptysBio's Imsidolimab Fails To Separate From Placebo In Skin Blistering Disorder Study
AnaptysBio Inc (NASDAQ: ANAB) reports disappointing top-line data from its Phase 2 (POPLAR) trial of imsidolimab for palmoplantar pustulosis (PPP). The study failed to meet its primary endpoint of impro...
Why AnaptysBio Was a Stock Market Star on Friday
There was some encouraging news from across the Atlantic.
Why AnaptysBio Fell by as Much as 10% Today
Perhaps no news is bad news for the ambitious biotech.
AnaptysBio, Inc. (ANAB) Earnings Expected to Grow: Should You Buy?
AnaptysBio, Inc. (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why AnaptysBio Trounced the Market on Thursday
The biotech got a sharp upward shift in recommendation and target price from a prominent analyst.
Why ESSA Pharma, AnaptysBio And More Are Moving Today
ESSA Pharma Inc. (NASDAQ: EPIX) shares are trading higher after the company reported first-quarter earnings results and highlighted the presentation of Phase 1 pharmacology data of EPI-7386 for advanced...